2015
Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China
Zhou W, Wang X, Zhou S, Xie N, Liu P, Luo L, Peng J, Liu M, Desrosiers A, Schottenfeld R, Chawarski MC. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction 2015, 110: 796-802. PMID: 25529103, PMCID: PMC4598328, DOI: 10.1111/add.12836.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentInjection drug useHCV seroconversionPatients HCVSeroconversion ratesDrug useOpiate positive urine testsHepatitis C virus infectionRisk behaviorsMethadone maintenance treatment patientsMethadone maintenance treatment programHepatitis C seroconversionC virus infectionUrine toxicology resultsHepatitis C virusMaintenance treatment programPotential risk factorsOpiate-dependent individualsCross-sectional surveyHCV seroprevalenceMMT clinicsMaintenance treatmentTreatment patientsC virusUrine tests
2012
Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
Ruger JP, Chawarski M, Mazlan M, Ng N, Schottenfeld R. Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia. PLOS ONE 2012, 7: e50673. PMID: 23226534, PMCID: PMC3514172, DOI: 10.1371/journal.pone.0050673.Peer-Reviewed Original ResearchConceptsHeroin dependenceCost-effectiveness ratioSecondary outcomesOutcome measuresDrug usePlacebo-controlled clinical trialFirst heroin useIncremental cost-effectiveness ratioSocietal costsInjection drug useSecondary outcome measuresPrimary outcome measureIllicit opiate useIncremental treatment costNaltrexone treatmentPrimary outcomeMedication costsPlacebo interventionClinical trialsHeroin abstinenceOpiate useHeroin useBuprenorphineTreatment retentionNaltrexoneLifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia
Chawarski MC, Vicknasingam B, Mazlan M, Schottenfeld RS. Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia. Drug And Alcohol Dependence 2012, 124: 177-180. PMID: 22266088, PMCID: PMC4641448, DOI: 10.1016/j.drugalcdep.2011.12.024.Peer-Reviewed Original ResearchConceptsOpiate injectorsHIV infectionHIV statusATS useLifetime historyAmphetamine-type stimulantsHIV-negative participantsHIV transmission riskHIV-positive participantsDrug use historyPublic health prevention measuresHigh-risk behaviorsHealth prevention measuresTreatment IDUsVs. 75HIV transmissionRisk factorsPositive participantsHIV riskHigh riskRisk behaviorsDrug abuse problemsTransmission riskDrug abuseIDUs
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependenceASIA PACIFIC COLUMN: New challenges and opportunities in managing substance abuse in Malaysia
MAZLAN M, SCHOTTENFELD RS, CHAWARSKI MC. ASIA PACIFIC COLUMN: New challenges and opportunities in managing substance abuse in Malaysia. Drug And Alcohol Review 2006, 25: 473-478. PMID: 16939945, DOI: 10.1080/09595230600883354.Peer-Reviewed Original ResearchConceptsStimulant abuseDrug useRelated disordersAgonist maintenance treatmentInjection drug useHealth careHigh HIV prevalenceHeroin-dependent individualsOpiate-dependent patientsSevere drug problemsInfectious disease ratesAgonist medicationsHIV casesMaintenance treatmentHIV prevalenceCountry's health careHeroin abusersMedical treatmentHeroin usersTreatment approachesDrug abusersDrug usersAdult populationDisease ratesSubstance abuseCoronary stenting is safe and effective in a high-risk octogenarian patient cohort.
Baklanov DV, Marcu CB, Juhasz DF, Caracciolo EA, Chawarski MC, Donohue TJ. Coronary stenting is safe and effective in a high-risk octogenarian patient cohort. Connecticut Medicine 2006, 70: 15-9. PMID: 16479871.Peer-Reviewed Original ResearchConceptsTarget vessel revascularization rateCoronary stentingProcedural successNew York Heart Association class IIIHigh procedural success rateSerial cardiac enzymesVessel revascularization ratePercent of patientsTIMI 3 flowAcute coronary syndromeMajor cardiac eventsProcedural success rateLow complication rateCoronary heart diseaseCommunity teaching hospitalHigh-risk populationLong-term resultsCoronary stent proceduresAngiographic profileCoronary syndromeIndex hospitalizationRevascularization ratesCardiac eventsComplication rateResidual stenosis